Table 1, Corticosteroids and disease-modifying antirheumatic drugs (DMARDs) approved by the U.S. Food and Drug Administration - Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update

Warning: The NCBI web site requires JavaScript to function. more...

Group	Names
Corticosteroids	Methylprednisolone, prednisone, prednisolone
csDMARDs	Hydroxychloroquine, leflunomide, methotrexate, sulfasalazine
TNF biologics	Adalimumab, certolizumab pegol, etanercept, golimumab, infliximab
Non-TNF biologics	Abatacept, rituximab, tocilizumab, sarilumab^a
tsDMARDs	Tofacitinib^a
Biosimilars	Adalimumab-atto,^a infliximab-dyyb,^a infliximab-abda,^a etanercept-szzs^a

a: New medications that the U.S. Food and Drug Administration has approved since 2012.
: csDMARD = conventional synthetic disease-modifying antirheumatic drug; TNF = tumor necrosis factor; tsDMARD = targeted synthetic disease-modifying antirheumatic drug.

Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update [Internet].

Comparative Effectiveness Review, No. 211.

Donahue KE, Gartlehner G, Schulman ER, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.